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Abstract Cytokines are part of pathogenesis in many
diseases. Their measurement could be interesting for
diagnostic purposes. One cytokine which participates in
different inflammatory and neoplastic diseases is
interleukin-6 (IL-6). The aim of this study was to
investigate the IL-6 serum concentration in dogs with
different liver diseases to show if there is any association
between the cytokine serum level and the disease aetiology
or the degree of the disease. IL-6 was measured in dogs
with acute hepatitis, chronic hepatitis of different degrees
and primary and secondary liver tumours. The data were
compared with clinically healthy dogs and dogs with extra-
hepatic diseases. For measurement, a commercial ELISA
Kit (R&D Systems) was used. Compared with clinically
healthy dogs and dogs with diabetes mellitus, all dogs with
an intra- or extra-hepatic inflammatory or neoplastic disease
have increased serum levels of IL-6. Dogs with acute
hepatitis have significantly increased IL-6 serum concen-
trations compared with dogs with chronic hepatitis (P<
0.05). No significant difference between mild and moderate
chronic hepatitis exists (P>0.05). Dogs with secondary
liver tumours have significantly increased IL-6 serum
concentrations in comparison to dogs with primary liver
tumours (P<0.01), but both groups have comparable IL-6
serum concentration to dogs with extra-hepatic tumours.
Measurement of IL-6 serum concentration may help
differentiate between acute and chronic hepatitis and
between primary and secondary liver tumours. Further
information about the aetiology of the liver disease cannot
be obtained by measuring IL-6 in the serum.
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Introduction
Cytokines are mediators of information transfer between
cells, and in this way, they regulate physiological and
pathological mechanisms in the body. They are potentially
of use in diagnosis. As a result of its function during
inflammatory processes and regeneration, interleukin-6
(IL-6) could be an interesting marker for liver diseases in
dogs. IL-6 is a protein that consists of 184 amino acids. It is
produced by lymphoid cells and by a variety of non-
lymphoid cells, including endothelial cells, epithelial cells
and fibroblasts (Kishimoto et al. 1995).
The synthesis and release of IL-6 are influenced by
various other cytokines and hormones. For example,
tumour necrosis factor-α, interleukin-1 and catecholamines
stimulate the synthesis of IL-6, whereas glucocorticoids
suppress it (Papanicolaou et al. 1998).
The target cells of IL-6 are lymphoid cells and other cells
such as hepatocytes and bone marrow cells (Barton 1997;
Papanicolaou et al. 1998). IL-6 acts on its target cells via
different transduction pathways, including those that involve
protein kinase C, cAMP/protein kinase A and the calcium
release pathway (Kamimura et al. 2003; Mitsuyama et al.
2006). The cytokine plays a role in different disease
mechanisms. Release of IL-6 occurs in cases of infection,
trauma and neoplasia, and its functions range from induction
S. Neumann (*) : S. Scheulen








Comp Clin Pathol (2012) 21:539–544
DOI 10.1007/s00580-010-1126-y
of acute-phase proteins to cell growth and differentiation
(Jakab and Kalabay 1998; Barrientos et al. 2008). A role is
described for IL-6, for example, in different autoimmune and
inflammatory diseases. In addition, IL-6 appears to have a
function in different diseases of bones and liver (Linker-
Israeli et al. 1991; Kotake et al. 1996; Chen et al. 2009;
Haedo et al. 2009; Tacke et al. 2009).
In hepatic diseases of humans, increased serum concen-
trations of IL-6 have been found in cases of hepatitis,
hepatic tumours and regeneration of the liver after different
insults (Lacour et al. 2005; Avrămescu et al. 2008; Wong et
al. 2009). Given its function in different disease mecha-
nisms, IL-6 could be an important parameter in clinical
pathology to describe the aetiology, severity and course of
diseases, and to determine the prognosis.
In this study, the serum concentration of IL-6 was
measured in dogs with different diseases of the liver. The
aim was to investigate the association of different liver
diseases and the serum concentration of IL-6. Furthermore,
the presence of a correlation between the degree of liver
disease and the serum concentration of IL-6 was investi-
gated. Finally, the serum concentration of IL-6 associated
with hepatic disease was compared with that in cases of




Thirty-five dogs with hepatic disease were included in this
study. The diagnosis of liver disease was based on the
anamnesis, the clinical investigation, clinical pathological
examination [alanine transferase (ALT); aspartate transfer-
ase (AST); glutamate dehydrogenase (GLDH); alkaline
phosphatase (ALP); fasting bile acids (BA); bilirubin
(BILI) and albumin (ALB)], ultrasound investigation and
histopathological diagnosis from a biopsy. The definitive
diagnosis was based on the histological investigation, and
the disease was classified according to the recommenda-
tions of the World Small Animal Veterinary Association
(WSAVA Liver Standardization Group 2006).
The IL-6 values of these dogs were compared with those
of 18 clinically healthy dogs. These dogs were presented
for vaccination and other routine examinations and had no
abnormalities in anamnesis, clinical investigation, clinical
biochemistry (ALT, AST, GLDH, ALP, BA, ALB, BILI,
creatinine, urea, phosphorus, calcium and glucose) and
haematology (e.g. white blood cells, packed cell volume).
Furthermore, no abnormalities were found in the liver
during ultrasound investigation of these dogs. Both groups
were compared with a group of 30 dogs with extra-hepatic
diseases. Ten dogs of this group had diabetes mellitus, ten
dogs had extra-hepatic inflammation and ten dogs had an
extra-hepatic tumour. All procedures of this study con-
formed to the German Protection of Animals Act.
Blood sampling and analysis
Blood samples were collected from the cephalic vein with a
22-g needle and were harvested in a plastic serum tube. The
samples were kept at room temperature for 15 min to allow
them to clot and were then centrifuged (10 min, 3,000×g).
Analysis of ALT, AST, GLDH, ALP, fasting BA, BILI and
ALB was performed according to standardised procedures
using an analyser (Konelab, Thermo Fisher Scientific) and
commercial kits. The serum for measurement of IL-6 was
frozen (−20°C) directly after clotting. The serum samples
were stored for no longer than 3 months before measure-
ments were made.
The concentration of IL-6 was measured using the
Canine IL-6 Duoset ELISA (catalogue number DY1609;
R&D Systems, Inc.). The analysis included plate prepara-
tion and assay procedure and was performed according to
the manufacturer’s ELISA protocol. Finally, the microtitre
plate was read using a microtitre reader (SLT Spectra,
Tecan) at 450 nm (correction wavelength 540 nm).
Biopsy and histology
The liver of each dog was evaluated by ultrasonography
(Megas, Esaote). The livers were examined for size, shape and
structure. Using a biopsy needle (True-cut, Surgivet) and
guided by ultrasound, three to four tissue samples were taken
from each structural lesion for further examination. The tissue
core specimens were 0.5–1.0 cm long and 2 mm thick. In
some cases, tissue samples were obtained at laparotomy. In
these cases, the dogs were investigated under general
anaesthesia (levomethadone, L-Polamivet®, Intervet; xyla-
zine, Rompun®, Bayer; isoflurane, Isoflurane®, Abbott).
Each tissue sample was fixed in 10% formaldehyde
solution. Tissue samples for histology were prepared and
stained with haematoxylin and eosin. The histological
diagnosis was performed by a board-certified pathologist.
The histopathological diagnosis corresponded to the recom-
mendations of the WSAVA Liver Standardization Group
(2006). The degree of hepatitis was assessed semi-
quantitatively.
Statistical analysis
The data from the dogs were split into different groups for
further statistical analysis. Group 1 comprised clinically
healthy dogs; group 2, dogs with acute hepatitis; group 3,
chronic hepatitis of mild degree; group 4, chronic hepatitis
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of moderate degree; group 5, liver tumours; group 5a,
primary liver tumours; group 5b, secondary liver tumours;
group 6, extra-hepatic inflammation; group 7, extra-hepatic
tumours and group 8, diabetes mellitus. The statistical
analysis was performed with the programme SAS System,
univariate procedure, version 8.1 (SAS Institute Inc.). The
data were checked for normal distribution with the
Shapiro–Wilk test.
The serum concentrations of IL-6 in all groups were
compared using the Mann–Whitney U test. The level of
significance was P<0.05.
The precision of the IL-6 ELISA was determined using
three serum samples on which ten consecutive runs were
performed during a single day. The day-to-day precision
was determined using three serum samples that were
evaluated once daily for 5 days. The mean, standard
deviation and coefficients of variation were calculated.
Results
The dogs with liver disease were divided into five groups,
depending on their histopathological diagnoses. Six dogs
had acute hepatitis, 13 dogs had chronic hepatitis and 16
dogs had a liver tumour. The six dogs with acute hepatitis
could be divided into three cases of acute purulent hepatitis,
one case of hepatitis associated with adenovirus infection,
one case associated with parvovirus infection and one case
associated with leptospirosis. The serum concentrations of
IL-6 in this group varied between 1 and 202 pg/mL, with an
average of 102 pg/mL (Fig. 1).
The group with chronic hepatitis consisted of 13 dogs, of
which eight had a mild degree of hepatitis and five had a
moderate degree. Reactive hepatitis, as a reaction of an
extra-hepatic disease, was excluded by histopathology;
those dogs were not considered in this study. The
concentration of IL-6 was between 6 and 67 pg/mL. The
average concentration in this group was 25 pg/mL (Fig. 1).
Sixteen dogs with liver tumours of different aetiologies
were included in this study. Hepatocellular carcinoma was
most frequently seen, with seven cases. Two cases of
cholangiocarcinoma were observed. In addition, two cases
of haemangiosarcoma, two cases of fibrosarcoma and three
cases of lymphoma were also included in the study. The
range of IL-6 concentrations in this group was from 3
to180 pg/mL, with an average concentration of 58 pg/mL
(Fig. 2). The average concentration of IL-6 in dogs with a
primary liver tumour (hepatocellular carcinoma, cholangio-
cellular carcinoma) was 31 pg/mL and that of dogs with
secondary liver tumours (lymphoma, haemangiosarcoma,
fibrosarcoma) was 91 pg/mL (Fig. 3).
We compared these data between the liver disease
groups and also compared them with data from healthy
controls. The serum concentrations of IL-6 in dogs with
different liver diseases were highly significantly (P<0.001)
increased compared with those of clinically healthy dogs.
The difference between acute and chronic hepatitis was also
significant (P<0.05). On the other hand, there was no
significant difference between dogs with mild and moderate
chronic hepatitis (Fig. 2).
The serum concentrations of IL-6 in dogs with different
liver tumours were highly significantly increased compared
with those of healthy dogs (P<0.001; Fig. 1). Dogs with
secondary liver tumours had significantly higher serum
concentrations of IL-6 than dogs with primary liver
Comparison of IL-6, group 1-8



















Fig. 1 Minimum, median, maximum and first and third quartiles of
IL-6 serum concentrations in groups 1 to 8 (group 1=healthy controls,
group 2=acute hepatitis, group 3=mild chronic hepatitis, group 4=
moderate chronic hepatitis, group 5=liver tumours [group 5a=primary
liver tumours, group 5b=secondary liver tumours], group 6=extra-
hepatic inflammation, group 7=extra-hepatic tumours and group 8=
diabetes mellitus)
Comparison of dogs with liver diseases (group 2,3,4,5)






















Fig. 2 Minimum, median, maximum and first and third quartiles of
IL-6 serum concentrations in groups 2 to 5. Significant differences are
indicated by asterisks
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tumours (P<0.01; Fig. 3). There was no significant
difference between dogs with acute hepatitis and dogs with
primary and secondary liver tumours (P>0.05; Fig. 2);
however, the difference between dogs with chronic hepatitis
and those with secondary liver tumours was highly
significant (P<0.001).
To detect differences in the serum concentration of IL-6
between dogs with intra- and extra-hepatic inflammatory
diseases or tumours, we compared the dogs with liver
disease in this study with dogs that had extra-hepatic
diseases. This group of dogs included ten dogs with an
extra-hepatic inflammatory process; two dogs in this group
had prostatitis and eight had pyometra. A further ten dogs
with an extra-hepatic tumour were included in this
comparison, comprising five cases of mammary carcinoma,
three cases of splenic haemangiosarcoma, one case of
bronchial carcinoma and one case of carcinoma of the
stomach. Finally, all data were compared with those from a
group of ten dogs with diabetes mellitus that had no
inflammatory or neoplastic disease.
No significant difference could be found between dogs
with acute hepatitis and those with extra-hepatic inflam-
mation (P>0.05); in contrast, the serum concentrations of
IL-6 in dogs with chronic hepatitis were significantly
lower than those in dogs with extra-hepatic inflammation
(P<0.01). The serum concentration of IL-6 in dogs with
intra- or extra-hepatic tumours showed no significant
difference (P>0.05). However, dogs with an extra-
hepatic inflammation or tumour had highly significantly
increased serum concentration of IL-6 compared with dogs
with diabetes mellitus (P<0.001; Fig. 1). Finally the intra-
and inter-assay precision of the IL-6 assay was 2.9% and
5.9%, respectively.
Discussion
The measurement of cytokines in diseased dogs is a new
field in clinical pathology. Given their function as media-
tors, cytokines can help to identify disease mechanisms, to
describe the course of disease and to assess prognosis. This
study focused on IL-6 in dogs with liver disease because
IL-6 has been shown to be critical for the acute-phase
response, for protection against hepatic injury and for liver
regeneration (Taub 2005; Berasain et al. 2009).
In clinically healthy dogs, the serum concentration of IL-
6 is very low. In this investigation, no healthy dog was
found with a serum concentration above 1 pg/mL.
Unfortunately, there is no study in which a reference
interval for IL-6 in dogs has been calculated. However, in
human studies with healthy controls, comparable serum
concentrations of about 1 pg/mL were reported (Benoy et
al. 2008; Salamon et al. 2008). Given this very low
reference range, the elevations of IL-6 associated with
different diseases can be recognised easily.
The results of this study showed that liver diseases of
different aetiologies were associated with elevated serum
concentrations of IL-6. This is in agreement with the results
of investigations in humans, which have involved measure-
ment of IL-6 in the serum of patients with different
neoplastic diseases, including metastases, and those with
non-neoplastic liver diseases. In both types of diseases, the
serum concentrations of IL-6 are increased compared with
those of controls (Matzaraki et al. 2007; Cheng et al. 2009).
The serum concentration of IL-6 in cases of acute
hepatitis is significantly higher than that in chronic
hepatitis. The pro-inflammatory function of IL-6 may
explain this finding. The release of different cytokines,
including IL-6, indicates the early beginning of an
inflammatory process (Eklund 2009). Measurement of a
significant difference in the level of IL-6 between acute and
chronic liver disease may help to differentiate between
these processes. Currently, there is no reliable blood
indicator of acute hepatitis. The results of this study show
that IL-6 could be helpful for identification of acute
hepatitis in dogs; however, the number of dogs with acute
hepatitis in this study was low, so further studies are
recommended with a larger number of patients.
Unfortunately, there was no significant difference in the
level of IL-6 between patients with mild and moderate
chronic hepatitis. In human patients with chronic hepatitis,
the serum concentration of IL-6 correlates with the degree
of fibrosis (Migita et al. 2006). Given that all the dogs with
chronic hepatitis in this study had a low degree of
inflammation and no or only mild fibrosis, dogs with
severe chronic hepatitis and fibrosis should be observed in
further studies to investigate the correlation between the
serum concentration of IL-6 and the degree of hepatitis.




















Fig. 3 Minimum, median, maximum and first and third quartiles of
IL-6 serum concentrations in groups 5a and 5b. Significant differences
are indicated by an asterisk
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All dogs with hepatitis in this study, both acute and
chronic, had comparable serum concentrations of IL-6 to
dogs with inflammatory diseases outside the liver, such as
prostatitis and pyometra. This supports the usefulness of
measuring IL-6 for identification of inflammatory process-
es. The concentration of IL-6 in dogs with chronic hepatitis
was lower than in the control group with extra-hepatic
inflammatory processes. One reason for this could be a
lower degree of inflammation in the group with chronic
hepatitis.
The dogs with liver tumours in this study also had
elevated serum concentrations of IL-6. The levels were
comparable to those in cases of acute hepatitis but higher
than in cases of chronic hepatitis. An explanation for this
could be the acute initiation of inflammation by mediators
in hepatic tumours and the resulting destruction of the liver
parenchyma. It could also be caused by attempts of the liver
to regenerate its tissue during neoplastic alteration. Eleva-
tion of IL-6 has also been reported in humans with liver
tumours of different aetiologies (Goydos et al. 1998; Cheng
et al. 2009).
Studies of liver tumours and serum concentrations of IL-
6 in dogs have not been published previously. It is
interesting that the concentrations of IL-6 in dogs with
secondary liver tumours were significantly higher than
those in dogs with primary liver tumours. In cases of
lymphoma, the release of IL-6 from lymphoid tumour cells
could explain this observation. In humans, serum concen-
trations of IL-6 are increased in patients with lymphoma,
and the levels fall during chemotherapy (Serebriakov et al.
1998).
To confirm that non-inflammatory and non-neoplastic
diseases have little influence on the serum concentration of
IL-6, we measured IL-6 in cases of diabetes mellitus and
compared these results with those from all cases of
inflammation or tumour. Like the healthy controls, the
dogs with diabetes mellitus have very low concentrations of
IL-6 in the serum. It can be concluded that the absence of
inflammatory processes is associated with a lack of IL-6
activation. On the other hand, in humans, secondary
inflammation associated with diabetes mellitus can induce
elevations of IL-6 (Goldberg 2009). This observation
requires investigation in further studies.
In conclusion, the results of our study show that IL-6
is measurable in dogs and that diseases of the liver are
associated with elevations of this cytokine. Differentia-
tion between acute and chronic hepatitis may be possible,
but the assessment of the degree of hepatitis is not
possible in milder cases. Dogs with liver tumours of
different aetiologies have elevated serum concentrations
of IL-6, and those with secondary liver tumours showed
significantly higher levels than those with primary
tumours or inflammatory diseases. The reason for this
is not clearly understood, but production of IL-6 by the
tumour cells could be one explanation. Further studies of
IL-6 and its involvement in liver disease in dogs are
necessary to investigate the prognostic use of IL-6 in
patients with liver diseases.
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